|Day Low/High||6.88 / 7.39|
|52 Wk Low/High||5.90 / 25.17|
Investors eyeing a purchase of NewLink Genetics Corp stock, but tentative about paying the going market price of $8.10/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the July put at the $6 strike, which has a bid at the time of this writing of $1.20.
Management to Host Conference Call Today at 4:30 p.m. ET
Investors in NewLink Genetics Corp saw new options become available this week, for the October 19th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 238 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.
Investors considering a purchase of NewLink Genetics Corp shares, but tentative about paying the going market price of $8.25/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the April put at the $6 strike, which has a bid at the time of this writing of $1.00.
Newman Ferrara LLP announced today that the firm is conducting an investigation on behalf of shareholders of NewLink Genetics Corporation ("NewLink" or the "Company") (NASDAQ:NLNK) into potential breaches of fiduciary duty...
NewLink Genetics updates financial and clinical guidance
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in NewLink Genetics Corp , where a total volume of 8,561 contracts has been traded thus far today, a contract volume which is representative of approximately 856,100 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 117.7% of NLNK's average daily trading volume over the past month, of 727,295 shares.
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.
- Management to Host Conference Call Today at 8:30 a.m. ET
The U.S. Food and Drug Administration has granted orphan drug designation to NewLink's indoximod, a potential treatment for patients with Stage IIb-IV melanoma.
Investors in NewLink Genetics Corp saw new options begin trading this week, for the November 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the NLNK options chain for the new November 17th contracts and identified one put and one call contract of particular interest.
NewLink Genetics Corporation ("NewLink Genetics") (Nasdaq:NLNK), a late-stage biopharmaceutical company, today announced that it intends to offer and sell, subject to market conditions, up to $50,000,000 of shares...
Phase 2, randomized, double-blind, placebo-controlled trial of indoximod in combination with durvalumab, an immune checkpoint inhibitor, along with gemcitabine/ABRAXANE® (nab-paclitaxel) and durvalumab with gemcitabine/ABRAXANE® versus gemcitabine/ABRAXANE®
NewLink Genetics Corporation (Nasdaq: NLNK) today announced that it has entered into a clinical collaboration agreement with AstraZeneca to evaluate the combination of indoximod, NewLink Genetics' small molecule IDO...
Investors eyeing a purchase of NewLink Genetics Corp shares, but tentative about paying the going market price of $11.04/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the April 2018 put at the $8 strike, which has a bid at the time of this writing of $1.25.
The company is scheduled Friday afternoon to present comprehensive data from its Phase 3 study of rucaparib at the European Society for Medical Oncology Congress in Madrid.
NewLink Genetics Corporation (NASDAQ: NLNK) today announced updated data from the ongoing Phase 2 NLG2103 study of indoximod, NewLink Genetics' IDO pathway inhibitor, in combination with the PD-1 pathway inhibitor,...
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.